These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29369973)

  • 21. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTOR inhibitors for management of encapsulating peritoneal sclerosis: a review of literatures.
    Ghadimi M; Dashti-Khavidaki S; Khalili H
    Ren Fail; 2016 Nov; 38(10):1574-1580. PubMed ID: 27425661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
    Franz DN; Capal JK
    Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.
    Kurdi A; Martinet W; De Meyer GRY
    Transplantation; 2018 Feb; 102(2S Suppl 1):S44-S46. PubMed ID: 28230638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.
    De Simone P; Fagiuoli S; Cescon M; De Carlis L; Tisone G; Volpes R; Cillo U;
    Transplantation; 2017 Feb; 101(2):239-251. PubMed ID: 27495768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology.
    Fogel AL; Hill S; Teng JM
    J Am Acad Dermatol; 2015 May; 72(5):879-89. PubMed ID: 25769191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse events associated with mTOR inhibitors.
    Pallet N; Legendre C
    Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors.
    Koletsa T; Petrakis G; Karayannopoulou G; Euvrard S; Kanitakis J
    Anticancer Res; 2018 Jun; 38(6):3319-3322. PubMed ID: 29848679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
    Klintmalm GB; Saab S; Hong JC; Nashan B
    Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR inhibitors for medical treatment of post-transplantation encapsulating peritoneal sclerosis: a favourable single center experience.
    Messina M; Ariaudo C; Mella A; Cantaluppi V; Segoloni GP; Biancone L
    J Nephrol; 2015 Apr; 28(2):245-9. PubMed ID: 25585825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
    Holdaas H; Potena L; Saliba F
    Transplant Rev (Orlando); 2015 Apr; 29(2):93-102. PubMed ID: 25227328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment.
    Merino D; San Segundo D; Medina JM; Rodrigo E; Asensio E; Irure J; Fernández-Fresnedo G; Arias MA; López-Hoyos M
    Immunology; 2016 Jun; 148(2):206-15. PubMed ID: 26931075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature.
    Framarino-dei-Malatesta M; Derme M; Manzia TM; Iaria G; De Luca L; Fazzolari L; Napoli A; Berloco P; Patel T; Orlando G; Tisone G
    Expert Rev Clin Immunol; 2013 Aug; 9(8):781-9. PubMed ID: 23971756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
    Garcia CA; Wu S
    Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
    Duvoux C; Toso C
    Transplant Rev (Orlando); 2015 Jul; 29(3):168-74. PubMed ID: 26071984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.